About the team
Four founders, the full arc
Computation, AI, the wet lab, and the clinic — each led by a domain expert.
AI-engine for combinatorial drug discovery
Biovizions designs drug combinations — not single molecules — engineered with AI for safer, smarter medicine.
How AI works today
AI drug discovery filters candidates before any wet-lab spend — moving failure out of the clinic and into the model.
Failure moves from Phase II (late, $100M+) to compute (early, near-zero).
Biovizions extends this from single molecules to designed combinations — applying the same compute-first rigor to pairings, not just one molecule at a time.
The unmet need
No single molecule beats biology fighting back. Push the dose to force efficacy, and it fails on three fronts.
Sources: Lancet GRAM 2024 (AMR) · FDA CDER (adverse drug reactions) · Watanabe et al. 2018 (morbidity cost).
High, constant dosing drives resistance. Designed combinations restore potency and outpace it.
Tumors escape single high-dose agents. Combinations block multiple escape routes at once.
Toxicity rises with dose. Lower-dose synergistic combinations widen the therapeutic window.
Our approach
Smarter medicine from old knowledge and new science — Biovizions uses AI to design drug combinations whose parts reinforce one another, so each works at a fraction of its solo dose.
Synergy lets each component do more with less.
Smaller, smarter doses widen the safety window.
Pairings that help more of the drug reach its target.
Old knowledge. New science. Smarter medicine.
About the team
Computation, AI, the wet lab, and the clinic — each led by a domain expert.
Contact
For research collaboration and partnership inquiries, we'd love to hear from you.
nachishankar@biovizions.com
